Logo - springer
Slogan - springer

Medicine - Oncology & Hematology | Cancer Immunology, Immunotherapy

Cancer Immunology, Immunotherapy

Cancer Immunology, Immunotherapy

Editors-in-Chief: G. Pawelec; S. Ostrand-Rosenberg

ISSN: 0340-7004 (print version)
ISSN: 1432-0851 (electronic version)

Journal no. 262

$199.00 Personal Rate e-only for the Americas
Get Subscription

Online subscription, valid from January through December of current calendar year

Immediate access to this year's issues via SpringerLink

1 Volume(-s) with 12 issue(-s) per annual subscription

Automatic annual renewal

More information: >> FAQs // >> Policy

Instructions for Authors

Types of Papers 

The journal Cancer Immunology, Immunotherapy publishes the following types of papers:
  • Original Article – word limit ca. 4000 words, ca. 45 references, no more than six figures/tables excluding supplementary on-line only material.
  • Letter to the Editors – CII occasionally accepts letters to the Editors pertaining primarily to articles published in the Journal. Text is limited to 750 words, with no abstract and no keywords, but including a précis. There may be one figure, up to three references, and no more than three authors, with author affiliations only including main institution, place name and (state plus) country (i.e. no departments, etc.). As for any other manuscript, the full details of the corresponding author and a conflict of interest statement must be included.
  • Opinion Paper – presents a novel or innovative interpretation of published data.
  • Commentary - discusses a paper(s) published in Cancer Immunology, Immunotherapy or elsewhere in which the authors of the Commentary provide additional data and insight that either support or refute the original publication.
  • Review – generally by invitation only, but unsolicited proposals accompanied by an abstract, and list of the authors' publications relevant to the topic under discussion can be sent to the Editors-in-Chief for consideration prior to submission.
  • Focussed Research Review – by invitation only. FRRs are based on presentations made at conferences, primarily intended to review the author´s own work in a particular area. They should provide the background for the "personal" review and not be a general overview of the field, and may present opinions or hypotheses. They may include original data, but previously published material must have copyright clearance. Articles should be 2,000-5,000 words, with a maximum of 50 references and 2-3 explanatory display items, preferably figures. They should include an abstract, but the remainder of the paper can be structured as desired as long as the general CII "Instructions for Authors" are adhered to. Manuscripts must be submitted as a Focussed Research Review (not as a Review) to the Editor-in-Chief who invited the submission. Specify the invitation (conference title, location and date) in the comments for the Editorial Office. FRRs are subject to the usual peer review process, and invitation to submit does not guarantee acceptance. Articles will be published on-line in the order of acceptance, but the print version will bring together all papers from a particular conference, together with a meeting report, if available.
  • Symposium-in-Writing Paper – by invitation only. SIW consist of a minimum of 3 articles, each written by different authors, focussed on a particular theme. They are from “virtual” symposia, not originating from a real-world conference and follow the guidelines for Focussed Research Reviews (see above). Individual SIW papers are submitted to the Editor-in-Chief who invited the SIW, and must indicate the title of the Symposium-in-Writing in comments for the Editorial Office. Investigators who would like to organize a “Symposium-in-Writing” on a special topic should contact the appropriate Editor-in-Chief.
  • Editorial – by invitation only.
  • Meeting Report – contact the Editor-in-Chief before submitting. Conference organizers should approach the appropriate EiC in advance of their meeting. CII is interested in the rapid publication of conference summaries. These should tell a scientific “story” and not be simply a list of speakers´ statements and must focus exclusively on the scientific activities of the conference. There is no formal limit to the length of meeting summaries but reports should be concise. The manuscript title must include the exact name of the conference and its acronym, the exact dates and the conference location (city and country). The title should not contain the words “meeting report” or anything like “report from”. Such manuscripts must be submitted without abstract, references, figures, tables, or photos. Meeting Reports must include a précis (see below) and conflict of interest statements for all authors. Cited speakers must be identified in bold type, followed by their institutions and locations in brackets. All cited speakers must approve the manuscript prior to submission and the submitting authors must confirm this approval in the comments for the Editorial Office. Meeting reports will be peer-reviewed by two meeting attendees and by two reviewers who did not attend the meeting. These reviewers must be suggested by the authors.
Meta-analysis
This contribution should be based on a rigorous methodological/statistical approach described in detail in the methods section applied to a relevant clinical or basic research issue. This work could also be submitted to statistical revision. Word limit is 3000 with no more than 100 references. Meta-Analyses and systematic reviews must adhere to the recommendations of the PRISMA document (http://prisma-statment.org).

Manuscript Submission 

Manuscript Submission

Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.

Permissions

Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.

Online Submission

Please follow the hyperlink “Submit online” on the right and upload all of your manuscript files following the instructions given on the screen.

Authorship, Criteria and Contributions

All authors must approve all versions of a submitted manuscript. All authors of accepted articles must accept responsibility for the manuscript’s content by signing an authorship form affirming that they have met the following three criteria for authorship:
1. Substantial contributions to conception and design, acquisition of data, and/or analysis and interpretation of results.
2. Substantial scientific and intellectual contributions to the drafting or rewriting of the initial and/or revised manuscript.
3. Approval of the final accepted version of the manuscript.
It is not sufficient merely to have provided funding or materials.

Redundant, Duplicate or Fraudulent Publication

  • Manuscripts submitted to Cancer Immunology, Immunotherapy must not be simultaneously submitted to another publication.
  • Manuscripts must contain original work that has not previously been published in other print or digital form except as an abstract at a conference. Such abstracts must be acknowledged in the submitted paper.
  • Manuscripts must not contain materials published in other print or electronic media without written permission from the relevant publisher. The publisher of Cancer Immunology, Immunotherapy will not be held legally responsible should there be any claims for compensation.
  • Manuscripts must not contain falsified data.
  • Manuscripts must not contain original data generated by non-authors.
  • Manuscripts must cite the work of other investigators which established priority.
  • Authors wishing to include figures, tables, or text passages that have been published elsewhere must obtain and submit written permission from the copyright owner(s) for both the print and on-line format at the time of initial manuscript submission. Any material received without such evidence will be assumed to originate from the authors.

Please note:

At the end of the submission process, carefully check the automatically-created PDF. It is the responsibility of the submitting author to ensure that this PDF contains the correct and complete text, graphic materials, symbols, mathematical signs, etc. Conversion problems can occur and if not corrected, may affect the evaluation of a manuscript.

Editorial Procedure 

Selection of Editor-in-Chief (for Manuscript Submission)

  • Dr. Suzanne Ostrand-Rosenberg is the Editor-in-Chief for manuscripts in which the reported studies were performed in the Americas, China or Japan.
  • Dr. Graham Pawelec is the Editor-in-Chief for manuscripts in which the reported studies were performed in all other countries.
Invited manuscripts are to be submitted to the Editor-in-Chief who issued the invitation and must specify the invitation in the comments for the Editorial Office.
Additional information: It is mandatory for authors to suggest at least 3 people who might review the manuscript. Please include E-mail addresses.

Review Procedures

Manuscripts are initially evaluated by the managing Editor-in-Chief according to the following criteria:
• Relevance to the aims of the Journal and the field of cancer immunology and immunotherapy.
• Subject matter that is of general interest to the readership of the Journal and will contribute to the advancement of the field.
• Originality.
• Appropriate study design and methodology.
• Conclusions which are supported by the data.
• Focussed and concise writing style.
Manuscripts that do not meet these criteria will be returned to the author without review.
Manuscripts that meet these criteria will be further evaluated by a minimum of two expert reviewers who will anonymously provide unbiased, critical and independent assessment of the submission. The Editor-in-Chief will make a final decision on the disposition of the manuscript based on the recommendations of these reviewers. Authors are encouraged to provide the full names and contact information of potential reviewers who have expertise in the subject of the manuscript. Authors may request the exclusion of specific reviewers and should provide justification for the request. The corresponding author will be notified of the editorial decision by E-mail which may include some or all of the reviewers' comments.

Revised Manuscripts

Manuscripts which are returned to the authors for minor or major modifications must be resubmitted within 6 months. Manuscripts not submitted within this timeframe will be withdrawn. If additional time is needed, the Editor-in-Chief must be contacted well before the manuscript is automatically withdrawn. A letter must accompany the revised manuscripts reiterating the reviewers' and Editor's comments and providing a point-by-point response to each of these comments. Revisions to the manuscript must be identified by highlighting with a gray or yellow background. "Tracking" mode in Word is not acceptable. Changes in the PDF of supplementary materials should not be highlighted, but must be explained in the point-by-point response. Only the highlighted version of the revised manuscript should be submitted; do not submit an additional “clean” version. Revised manuscripts will be re-evaluated by the external reviewers who will assess new data and determine if the authors have satisfactorily responded to the initial critiques. Depending on this evaluation, the manuscript may be accepted or rejected at the discretion of the Editor-in-Chief. Questions or concerns regarding an editorial decision must be submitted within one month of completion of the review.

Confidentiality

All manuscripts are treated as privileged and confidential information. Reviewers may request advice from another party, subject to the general principles of confidentiality and permission of the Editor-in-Chief. Invited reviewers unable to accept an invitation to assess a paper are encouraged to suggest alternative reviewers; however, an invited reviewer must not pass any manuscript to another person without prior approval of the Editor-in-Chief. Reviewers’ comments are not published or made available publicly except with the prior written permission of the reviewer, author, and Editor-in-Chief. However, all reviewer comments for the authors are visible to all other reviewers of the same manuscript. The reviewers’ identities remain undisclosed. Reviewers must consider potential conflicts of interest that could influence their recommendations and if necessary discuss these with the Editor-in-Chief prior to undertaking the review.

Title page 

Title Page

The title page should include:
  • The name(s) of the author(s)
  • A concise and informative title
  • The affiliation(s) and address(es) of the author(s)
  • The e-mail address, and telephone number(s) of the corresponding author
  • If available, the 16-digit ORCID of the author(s)

Abstract

Please provide an abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified references.

Keywords

Please provide 4 to 6 keywords which can be used for indexing purposes.

Précis

  • Provide one or two succinct sentences (not just keywords) highlighting what makes the manuscript especially interesting and significant. The précis will be included in the table of contents alerts and must not exceed 250 characters, including spaces. It must not be written in the first person (I, we, my, our), must not include the word “manuscript” and should not repeat the title.

Introduction, Materials and Methods, Results and Discussion

  • The Introduction must provide sufficient background to understand the significance of the content but should not include a general review of the field.
  • Materials and Methods must contain sufficient information so that experimental procedures can be reproduced. Materials and Methods or parts thereof must not be transferred into the supplementary, on-line only materials. If animals and/or human subjects were used, a statement documenting the approval of their use must be included. The Editors encourage but do not require that papers describing T cell assays with human cells comply with the MIATA recommendations for reporting such methods. These recommendations may be seen at http://miataproject.org/. If applied, the authors should provide a statement that their paper is MIATA-compliant and should include the MIATA checklist in the “Supplementary” files. Accepted papers following MIATA guidelines will be prominently labeled as such in their published version, and contain the statement “The authors of this paper report on their T cell assays transparently and comprehensively as per field-wide consensus, allowing the community a full understanding and interpretation of presented data as well as a comparison of data between groups.”
The Discussion follows the Results section and must interpret the experimental findings in the context of the state-of-the-art and not simply reiterate data in the Results.

Text 

Text Formatting

Manuscripts should be submitted in Word.
  • Use a normal, plain font (e.g., 10-point Times Roman) for text.
  • Use italics for emphasis.
  • Use the automatic page numbering function to number the pages.
  • Do not use field functions.
  • Use tab stops or other commands for indents, not the space bar.
  • Use the table function, not spreadsheets, to make tables.
  • Use the equation editor or MathType for equations.
  • Save your file in docx format (Word 2007 or higher) or doc format (older Word versions).
Manuscripts with mathematical content can also be submitted in LaTeX.

Headings

Please use no more than three levels of displayed headings.

Abbreviations

Abbreviations should be defined at first mention and used consistently thereafter.

Footnotes

Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables.
Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols.
Always use footnotes instead of endnotes.

Acknowledgments

Acknowledgments of people, grants, funds, etc. should be placed in a separate section on the title page. The names of funding organizations should be written in full.

Specific Remark on Abbreviations

Non-standard abbreviations should be defined on the cover page and at first mention in the text and used consistently thereafter.

Scientific style 

  • Please always use internationally accepted signs and symbols for units (SI units).
  • Nomenclature: Insofar as possible, authors should use systematic names similar to those used by Chemical Abstract Service or IUPAC.
  • Genus and species names should be in italics.
  • Generic names of drugs and pesticides are preferred; if trade names are used, the generic name should be given at first mention.

References 

Citation

Reference citations in the text should be identified by numbers in square brackets. Some examples:
1. Negotiation research spans many disciplines [3].
2. This result was later contradicted by Becker and Seligman [5].
3. This effect has been widely studied [1-3, 7].

Reference list

The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a reference list.
The entries in the list should be numbered consecutively.
  • Journal article
    Gamelin FX, Baquet G, Berthoin S, Thevenet D, Nourry C, Nottin S, Bosquet L (2009) Effect of high intensity intermittent training on heart rate variability in prepubescent children. Eur J Appl Physiol 105:731-738. https://doi.org/10.1007/s00421-008-0955-8
    Ideally, the names of all authors should be provided, but the usage of “et al” in long author lists will also be accepted:
    Smith J, Jones M Jr, Houghton L et al (1999) Future of health insurance. N Engl J Med 965:325–329
  • Article by DOI
    Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine production. J Mol Med. https://doi.org/10.1007/s001090000086
  • Book
    South J, Blass B (2001) The future of modern genomics. Blackwell, London
  • Book chapter
    Brown B, Aaron M (2001) The politics of nature. In: Smith J (ed) The rise of modern genomics, 3rd edn. Wiley, New York, pp 230-257
  • Online document
    Cartwright J (2007) Big stars have weather too. IOP Publishing PhysicsWeb. http://physicsweb.org/articles/news/11/6/16/1. Accessed 26 June 2007
  • Dissertation
    Trent JW (1975) Experimental acute renal failure. Dissertation, University of California
Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word Abbreviations, see
If you are unsure, please use the full journal title.
For authors using EndNote, Springer provides an output style that supports the formatting of in-text citations and reference list.
Authors preparing their manuscript in LaTeX can use the bibtex file spbasic.bst which is included in Springer’s LaTeX macro package.

Tables 

  • All tables are to be numbered using Arabic numerals.
  • Tables should always be cited in text in consecutive numerical order.
  • For each table, please supply a table caption (title) explaining the components of the table.
  • Identify any previously published material by giving the original source in the form of a reference at the end of the table caption.
  • Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data) and included beneath the table body.

Artwork and Illustrations Guidelines 

Electronic Figure Submission

  • Supply all figures electronically.
  • Indicate what graphics program was used to create the artwork.
  • For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MSOffice files are also acceptable.
  • Vector graphics containing fonts must have the fonts embedded in the files.
  • Name your figure files with "Fig" and the figure number, e.g., Fig1.eps.

Line Art

Line BW
  • Definition: Black and white graphic with no shading.
  • Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible at final size.
  • All lines should be at least 0.1 mm (0.3 pt) wide.
  • Scanned line drawings and line drawings in bitmap format should have a minimum resolution of 1200 dpi.
  • Vector graphics containing fonts must have the fonts embedded in the files.

Halftone Art

Halftone gray color
  • Definition: Photographs, drawings, or paintings with fine shading, etc.
  • If any magnification is used in the photographs, indicate this by using scale bars within the figures themselves.
  • Halftones should have a minimum resolution of 300 dpi.

Combination Art

Combined
  • Definition: a combination of halftone and line art, e.g., halftones containing line drawing, extensive lettering, color diagrams, etc.
  • Combination artwork should have a minimum resolution of 600 dpi.

Color Art

  • Color art is free of charge for online publication.
  • If black and white will be shown in the print version, make sure that the main information will still be visible. Many colors are not distinguishable from one another when converted to black and white. A simple way to check this is to make a xerographic copy to see if the necessary distinctions between the different colors are still apparent.
  • If the figures will be printed in black and white, do not refer to color in the captions.
  • Color illustrations should be submitted as RGB (8 bits per channel).

Figure Lettering

  • To add lettering, it is best to use Helvetica or Arial (sans serif fonts).
  • Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm (8–12 pt).
  • Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an axis and 20-pt type for the axis label.
  • Avoid effects such as shading, outline letters, etc.
  • Do not include titles or captions within your illustrations.

Figure Numbering

  • All figures are to be numbered using Arabic numerals.
  • Figures should always be cited in text in consecutive numerical order.
  • Figure parts should be denoted by lowercase letters (a, b, c, etc.).
  • If an appendix appears in your article and it contains one or more figures, continue the consecutive numbering of the main text. Do not number the appendix figures,
    "A1, A2, A3, etc." Figures in online appendices (Electronic Supplementary Material) should, however, be numbered separately.

Figure Captions

  • Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file.
  • Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type.
  • No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.
  • Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.
  • Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.

Figure Placement and Size

  • Figures should be submitted separately from the text, if possible.
  • When preparing your figures, size figures to fit in the column width.
  • For most journals the figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide and not higher than 234 mm.
  • For books and book-sized journals, the figures should be 80 mm or 122 mm wide and not higher than 198 mm.

Permissions

If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used.

Accessibility

In order to give people of all abilities and disabilities access to the content of your figures, please make sure that
  • All figures have descriptive captions (blind users could then use a text-to-speech software or a text-to-Braille hardware)
  • Patterns are used instead of or in addition to colors for conveying information (colorblind users would then be able to distinguish the visual elements)
  • Any figure lettering has a contrast ratio of at least 4.5:1

Cover Art 

Cancer Immunology, Immunotherapy welcomes suggestions of material as potential cover art. After a manuscript is accepted for publication, the corresponding author may contact the Editor-in-Chief or the Editorial Office with suitable material that illustrates the significance/impact of the paper. This material should be in color and can be a figure from the manuscript, a modification of a figure from the manuscript, a schematic illustration of the study, or any combination of these and/or other relevant materials. The material must be formatted according to the guidelines for graphic art (see below) and be sized to fit within an 8.41 cm (height) by 12.28 cm (width) space.

Electronic Supplementary Material 

(On-line Only Materials)

  • Cancer Immunology, Immunotherapy accepts figures, tables, the above mentioned MIATA checklist and small videos as supplementary, on-line materials.
  • All Materials and Methods must be included in the manuscript text; they must not be in the on-line only materials.
  • Electronic supplementary materials will be published as submitted without conversion, editing, or reformatting.
  • Each supplementary item (figure, table, video, etc.) must be numbered and cited in the text in the numerical order in which it appears, and must be called “supplementary figure”, "supplementary table", "supplementary media”, "supplementary video", "supplementary audio", “supplementary animation", or "supplementary MIATA information."
  • The MPEG-1 (.mpg) format is used for audio, video, and animations. Large-sized files may require very long download times and be problematic to upload.
  • Other on-line only materials must be submitted as PDFs. Supplementary tables and figures must be included in a single PDF starting with “supplementary Table 1” (followed by all other supplementary tables) or "supplementary Figure 1" (followed by all other supplementary figures). A title and caption for figures or a legend for tables must appear immediately below each figure or table. Supplementary figure captions and supplementary table legends must not be included in the manuscript text.
  • Supplementary materials must contain only the supplementary figure, table, video etc. and relevant caption. No other information should be included in the PDF (i.e. do not include authors' names, institutional affiliations, date, etc.) except for the journal name (Cancer Immunology, Immunotherapy), followed by the year of submission in parentheses and by the full name of the first author. Example: Cancer Immunology, Immunotherapy (submitted in 2015) - John Smith et al.
  • Revisions must not be highlighted in on-line only materials, but should be explained in the point-by-point response to the reviewer comments.
  • On publication, supplementary files will be named (Electronic) Supplementary Material (1), (2), etc.

Ethical Responsibilities of Authors 

This journal is committed to upholding the integrity of the scientific record. As a member of the Committee on Publication Ethics (COPE) the journal will follow the COPE guidelines on how to deal with potential acts of misconduct.
Authors should refrain from misrepresenting research results which could damage the trust in the journal, the professionalism of scientific authorship, and ultimately the entire scientific endeavour. Maintaining integrity of the research and its presentation can be achieved by following the rules of good scientific practice, which include:
  • The manuscript has not been submitted to more than one journal for simultaneous consideration.
  • The manuscript has not been published previously (partly or in full), unless the new work concerns an expansion of previous work (please provide transparency on the re-use of material to avoid the hint of text-recycling (“self-plagiarism”)).
  • A single study is not split up into several parts to increase the quantity of submissions and submitted to various journals or to one journal over time (e.g. “salami-publishing”).
  • No data have been fabricated or manipulated (including images) to support your conclusions
  • No data, text, or theories by others are presented as if they were the author’s own (“plagiarism”). Proper acknowledgements to other works must be given (this includes material that is closely copied (near verbatim), summarized and/or paraphrased), quotation marks are used for verbatim copying of material, and permissions are secured for material that is copyrighted.
    Important note: the journal may use software to screen for plagiarism.
  • Consent to submit has been received explicitly from all co-authors, as well as from the responsible authorities - tacitly or explicitly - at the institute/organization where the work has been carried out, before the work is submitted.
  • Authors whose names appear on the submission have contributed sufficiently to the scientific work and therefore share collective responsibility and accountability for the results.
  • Authors are strongly advised to ensure the correct author group, corresponding author, and order of authors at submission. Changes of authorship or in the order of authors are not accepted after acceptance of a manuscript.
  • Adding and/or deleting authors at revision stage may be justifiably warranted. A letter must accompany the revised manuscript to explain the role of the added and/or deleted author(s). Further documentation may be required to support your request.
  • Requests for addition or removal of authors as a result of authorship disputes after acceptance are honored after formal notification by the institute or independent body and/or when there is agreement between all authors.
  • Upon request authors should be prepared to send relevant documentation or data in order to verify the validity of the results. This could be in the form of raw data, samples, records, etc. Sensitive information in the form of confidential proprietary data is excluded.
If there is a suspicion of misconduct, the journal will carry out an investigation following the COPE guidelines. If, after investigation, the allegation seems to raise valid concerns, the accused author will be contacted and given an opportunity to address the issue. If misconduct has been established beyond reasonable doubt, this may result in the Editor-in-Chief’s implementation of the following measures, including, but not limited to:
  • If the article is still under consideration, it may be rejected and returned to the author.
  • If the article has already been published online, depending on the nature and severity of the infraction, either an erratum will be placed with the article or in severe cases complete retraction of the article will occur. The reason must be given in the published erratum or retraction note. Please note that retraction means that the paper is maintained on the platform, watermarked "retracted" and explanation for the retraction is provided in a note linked to the watermarked article.
  • The author’s institution may be informed.

Compliance with Ethical Standards 

To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals.
Authors should include the following statements (if applicable) in a separate section entitled “Compliance with Ethical Standards” when submitting a paper:
  • Disclosure of potential conflicts of interest
  • Research involving Human Participants and/or Animals
  • Informed consent
Please note that standards could vary slightly per journal dependent on their peer review policies (i.e. single or double blind peer review) as well as per journal subject discipline. Before submitting your article check the instructions following this section carefully.
The corresponding author should be prepared to collect documentation of compliance with ethical standards and send if requested during peer review or after publication.
The Editors reserve the right to reject manuscripts that do not comply with the above-mentioned guidelines. The author will be held responsible for false statements or failure to fulfill the above-mentioned guidelines.

Disclosure of potential conflicts of interest 

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of a real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. Examples of potential conflicts of interests that are directly or indirectly related to the research may include but are not limited to the following:
  • Research grants from funding agencies (please give the research funder and the grant number)
  • Honoraria for speaking at symposia
  • Financial support for attending symposia
  • Financial support for educational programs
  • Employment or consultation
  • Support from a project sponsor
  • Position on advisory board or board of directors or other type of management relationships
  • Multiple affiliations
  • Financial relationships, for example equity ownership or investment interest
  • Intellectual property rights (e.g. patents, copyrights and royalties from such rights)
  • Holdings of spouse and/or children that may have financial interest in the work
In addition, interests that go beyond financial interests and compensation (non-financial interests) that may be important to readers should be disclosed. These may include but are not limited to personal relationships or competing interests directly or indirectly tied to this research, or professional interests or personal beliefs that may influence your research.
The corresponding author collects the conflict of interest disclosure forms from all authors. In author collaborations where formal agreements for representation allow it, it is sufficient for the corresponding author to sign the disclosure form on behalf of all authors. Examples of forms can be found
The corresponding author will include a summary statement in the text of the manuscript in a separate section before the reference list, that reflects what is recorded in the potential conflict of interest disclosure form(s).
See below examples of disclosures:
Funding: This study was funded by X (grant number X).
Conflict of Interest: Author A has received research grants from Company A. Author B has received a speaker honorarium from Company X and owns stock in Company Y. Author C is a member of committee Z.
If no conflict exists, the authors should state:
Conflict of Interest: The authors declare that they have no conflict of interest.

Research involving human participants and/or animals 

1) Statement of human rights

When reporting studies that involve human participants, authors should include a statement that the studies have been approved by the appropriate institutional and/or national research ethics committee and have been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
If doubt exists whether the research was conducted in accordance with the 1964 Helsinki Declaration or comparable standards, the authors must explain the reasons for their approach, and demonstrate that the independent ethics committee or institutional review board explicitly approved the doubtful aspects of the study.
The following statements should be included in the text before the References section:
Ethical approval: “All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.”
For retrospective studies, please add the following sentence:
“For this type of study formal consent is not required.”

2) Statement on the welfare of animals

The welfare of animals used for research must be respected. When reporting experiments on animals, authors should indicate whether the international, national, and/or institutional guidelines for the care and use of animals have been followed, and that the studies have been approved by a research ethics committee at the institution or practice at which the studies were conducted (where such a committee exists).
For studies with animals, the following statement should be included in the text before the References section:
Ethical approval: “All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.”
If applicable (where such a committee exists): “All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.”
If articles do not contain studies with human participants or animals by any of the authors, please select one of the following statements:
“This article does not contain any studies with human participants performed by any of the authors.”
“This article does not contain any studies with animals performed by any of the authors.”
“This article does not contain any studies with human participants or animals performed by any of the authors.”

Informed consent 

All individuals have individual rights that are not to be infringed. Individual participants in studies have, for example, the right to decide what happens to the (identifiable) personal data gathered, to what they have said during a study or an interview, as well as to any photograph that was taken. Hence it is important that all participants gave their informed consent in writing prior to inclusion in the study. Identifying details (names, dates of birth, identity numbers and other information) of the participants that were studied should not be published in written descriptions, photographs, and genetic profiles unless the information is essential for scientific purposes and the participant (or parent or guardian if the participant is incapable) gave written informed consent for publication. Complete anonymity is difficult to achieve in some cases, and informed consent should be obtained if there is any doubt. For example, masking the eye region in photographs of participants is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic profiles, authors should provide assurance that alterations do not distort scientific meaning.
The following statement should be included:
Informed consent: “Informed consent was obtained from all individual participants included in the study.”
If identifying information about participants is available in the article, the following statement should be included:
“Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.”

English Language Editing 

For editors and reviewers to accurately assess the work presented in your manuscript you need to ensure the English language is of sufficient quality to be understood. If you need help with writing in English you should consider:
  • Asking a colleague who is a native English speaker to review your manuscript for clarity.
  • Visiting the English language tutorial which covers the common mistakes when writing in English.
  • Using a professional language editing service where editors will improve the English to ensure that your meaning is clear and identify problems that require your review. Two such services are provided by our affiliates Nature Research Editing Service and American Journal Experts. Springer authors are entitled to a 10% discount on their first submission to either of these services, simply follow the links below.
Please note that the use of a language editing service is not a requirement for publication in this journal and does not imply or guarantee that the article will be selected for peer review or accepted.
If your manuscript is accepted it will be checked by our copyeditors for spelling and formal style before publication.

.

为便于编辑和评审专家准确评估您稿件中陈述的研究工作,您需要确保您的英语语言质量足以令人理解。如果您需要英文写作方面的帮助,您可以考虑:
● 请一位以英语为母语的同事审核您的稿件是否表意清晰。
● 查看一些有关英语写作中常见语言错误的教程。
● 使用专业语言编辑服务,编辑人员会对英语进行润色,以确保您的意思表达清晰,并识别需要您复核的问题。我们的附属机构 Nature Research Editing Service 和合作伙伴 American Journal Experts 即可提供此类服务。
请注意,使用语言编辑服务并非在期刊上发表文章的必要条件,同时也并不意味或保证文章将被选中进行同行评议或被接受。
如果您的稿件被接受,在发表之前,我们的文字编辑会检查您的文稿拼写是否规范以及文体是否正式。

.

エディターと査読者があなたの論文を正しく評価するには、使用されている英語の質が十分に高いことが必要とされます。英語での論文執筆に際してサポートが必要な場合には、次のオプションがあります:
・英語を母国語とする同僚に、原稿で使用されている英語が明確であるかをチェックしてもらう。
・英語で執筆する際のよくある間違いに関する英語のチュートリアルを参照する。
・プロの英文校正サービスを利用する。校正者が原稿の意味を明確にしたり、問題点を指摘し、英語の質を向上させます。Nature Research Editing Service とAmerican Journal Experts の2つは弊社と提携しているサービスです。Springer の著者は、いずれのサービスも初めて利用する際には10%の割引を受けることができます。以下のリンクを参照ください。
英文校正サービスの利用は、投稿先のジャーナルに掲載されるための条件ではないこと、また論文審査や受理を保証するものではないことに留意してください。
原稿が受理されると、出版前に弊社のコピーエディターがスペルと体裁のチェックを行います。

.

영어 원고의 경우, 에디터 및 리뷰어들이 귀하의 원고에 실린 결과물을 정확하게 평가할 수 있도록, 그들이 충분히 이해할 수 있을 만한 수준으로 작성되어야 합니다. 만약 영작문과 관련하여 도움을 받기를 원하신다면 다음의 사항들을 고려하여 주십시오:
• 귀하의 원고의 표현을 명확히 해줄 영어 원어민 동료를 찾아서 리뷰를 의뢰합니다.
• 영어 튜토리얼 페이지에 방문하여 영어로 글을 쓸 때 자주하는 실수들을 확인합니다.
• 리뷰에 대비하여, 원고의 의미를 명확하게 해주고 리뷰에서 요구하는 문제점들을 식별해서 영문 수준을 향상시켜주는 전문 영문 교정 서비스를 이용합니다. Nature Research Editing Service와 American Journal Experts에서 저희와 협약을 통해 서비스를 제공하고 있습니다. Springer 저자들이 본 교정 서비스를 첫 논문 투고를 위해 사용하시는 경우 10%의 할인이 적용되며, 아래의 링크를 통하여 확인이 가능합니다.
영문 교정 서비스는 게재를 위한 요구사항은 아니며, 해당 서비스의 이용이 피어 리뷰에 논문이 선택되거나 게재가 수락되는 것을 의미하거나 보장하지 않습니다.
원고가 수락될 경우, 출판 전 저희측 편집자에 의해 원고의 철자 및 문체를 검수하는 과정을 거치게 됩니다.

After Acceptance 

Upon acceptance of your article you will receive a link to the special Author Query Application at Springer’s web page where you can sign the Copyright Transfer Statement online and indicate whether you wish to order OpenChoice and offprints.
Once the Author Query Application has been completed, your article will be processed and you will receive the proofs.

Copyright transfer

Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher exclusive publication and dissemination rights). This will ensure the widest possible protection and dissemination of information under copyright laws.

Offprints

Offprints can be ordered by the corresponding author.

Color illustrations

Publication of color illustrations is free of charge.

Proof reading

The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor.
After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article.

Online First

The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers.

Open Choice 

In addition to the normal publication process (whereby an article is submitted to the journal and access to that article is granted to customers who have purchased a subscription), Springer provides an alternative publishing option: Springer Open Choice. A Springer Open Choice article receives all the benefits of a regular subscription-based article, but in addition is made available publicly through Springer’s online platform SpringerLink.

Copyright and license term – CC BY

Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution License.

Read this Journal on Springerlink

For authors and editors


  • Journal Citation Reports®
    2016 Impact Factor
  • 4.711
  • Aims and Scope

    Aims and Scope

    Close

    Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts.

    In addition to publishing original research articles and reviews, CII also offers the following unique publication formats:

    ·         “Focussed Research Reviews,” published together with a conference meeting report, which provide individual speakers with the opportunity to expand on the ideas and concepts they presented at the conference.

    ·         “Symposia-in-Writing,” which are virtual workshops consisting of a series of complimentary papers centered on a specific issue and addressing controversial but strategic topics in the field, usually consisting of 4-8 papers and an accompanying commentary by the convener.

     CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), Sociedad Española de Immunologia-Grupo Español de ImmunoTerapia (SEI-GEIT), and Cancer Immunotherapy & Immunomonitoring (CITIM).

  • Submit Online
  • Open Choice - Your Way to Open Access
  • Instructions for Authors

    Instructions for Authors

    Close

  • Resources for Journal Authors
  • Author Academy: Training for Authors
  • Free Access Articles

    Free Access Articles

    Close

  • Copyright Information

    Copyright Information

    Close

    Copyright Information

    For Authors

    Submission of a manuscript implies: that the work described has not been published before (except in form of an abstract or as part of a published lecture, review or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all co-authors, if any, as well as – tacitly or explicitly – by the responsible authorities at the institution where the work was carried out.

    Author warrants (i) that he/she is the sole owner or has been authorized by any additional copyright owner to assign the right, (ii) that the article does not infringe any third party rights and no license from or payments to a third party is required to publish the article and (iii) that the article has not been previously published or licensed. The author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors. Transfer of copyright to Springer (respective to owner if other than Springer) becomes effective if and when a Copyright Transfer Statement is signed or transferred electronically by the corresponding author. After submission of the Copyright Transfer Statement signed by the corresponding author, changes of authorship or in the order of the authors listed will not be accepted by Springer.

    The copyright to this article, including any graphic elements therein (e.g. illustrations, charts, moving images), is assigned for good and valuable consideration to Springer effective if and when the article is accepted for publication and to the extent assignable if assignability is restricted for by applicable law or regulations (e.g. for U.S. government or crown employees).

    The copyright assignment includes without limitation the exclusive, assignable and sublicensable right, unlimited in time and territory, to reproduce, publish, distribute, transmit, make available and store the article, including abstracts thereof, in all forms of media of expression now known or developed in the future, including pre- and reprints, translations, photographic reproductions and microform. Springer may use the article in whole or in part in electronic form, such as use in databases or data networks for display, print or download to stationary or portable devices. This includes interactive and multimedia use and the right to alter the article to the extent necessary for such use.

    Authors may self-archive the Author's accepted manuscript of their articles on their own websites. Authors may also deposit this version of the article in any repository, provided it is only made publicly available 12 months after official publication or later. He/she may not use the publisher's version (the final article), which is posted on SpringerLink and other Springer websites, for the purpose of self-archiving or deposit. Furthermore, the Author may only post his/her version provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".

    Prior versions of the article published on non-commercial pre-print servers like arXiv.org can remain on these servers and/or can be updated with Author's accepted version. The final published version (in pdf or html/xml format) cannot be used for this purpose. Acknowledgement needs to be given to the final publication and a link must be inserted to the published article on Springer's website, accompanied by the text "The final publication is available at link.springer.com". Author retains the right to use his/her article for his/her further scientific career by including the final published journal article in other publications such as dissertations and postdoctoral qualifications provided acknowledgement is given to the original source of publication.

    Author is requested to use the appropriate DOI for the article. Articles disseminated via link.springer.com are indexed, abstracted and referenced by many abstracting and information services, bibliographic networks, subscription agencies, library networks, and consortia.

    For Readers

    While the advice and information in this journal is believed to be true and accurate at the date of its publication, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may have been made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

    All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher (respective the copyright owner if other than Springer). The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

    Springer has partnered with Copyright Clearance Center's RightsLink service to offer a variety of options for reusing Springer content. For permission to reuse our content please locate the material that you wish to use on link.springer.com or on springerimages.com and click on the permissions link or go to copyright.com, then enter the title of the publication that you wish to use. For assistance in placing a permission request, Copyright Clearance Center can be connected directly via phone: +1-855-239-3415, fax: +1-978-646-8600, or e-mail: info@copyright.com.


    © Springer-Verlag Berlin Heidelberg

Services for the Journal

Alerts for this journal

 

Get the table of contents of every new issue published in Cancer Immunology, Immunotherapy.


Additional information